CD34+ cells mobilized for aHCT in patients that later developed t-MDS/AML have been shown to present alterations in their DSB repair pathway as measured by microarray analysis [60] and it is possible that the repair deficiency post-aHCT was already present prior to the transplant, although possibly only in a subset of cells. The gene discussed is CD34; the disease is myelodysplastic syndrome.